ºÚÁϳԹÏÍø

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • ºÚÁϳԹÏÍø News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, May 7 2026

Full Issue

Research Roundup: The Latest Science, Discoveries, And Breakthroughs

Each week, ºÚÁϳԹÏÍø News compiles a selection of health policy studies and briefs.

In a large new review, published today in the Annals of Internal Medicine, researchers analyzed 43 clinical trials involving adults with chronic migraine, defined as headaches on 15 or more days a month. The strongest evidence pointed to a newer class of medications called CGRP-targeted therapies, according to the results. These drugs were shown to reduce monthly migraine days by about two and were generally well tolerated. (5/5)

People who used calcitonin gene-related peptide (CGRP) inhibitor drugs to prevent migraine had a lower risk of glaucoma, a retrospective study showed. (George, 5/6)

Ketamine infusion rapidly reduced suicidal and depressive symptoms among patients with a major depressive episode, according to findings from a systematic review and meta-analysis. (Firth, 5/6)

Depression treatments focus mostly on decreasing negative emotions. But a study finds that increasing positive ones might be more effective. (Penman, 5/6)

Hard hits taken by football players jar more than just their brains, a new study says. Head impacts appear to disrupt players’ gut microbiome, the colony of bacteria and organisms in the GI tract that help regulate inflammation, digestion and many other body processes, researchers reported May 6 in the journal PLOS One. Even impacts that didn’t cause symptoms of concussion shook up players’ gut bacteria, researchers found. (Thompson, 5/7)

People recovering from surgery have an easy way to boost their odds of a successful recuperation — take a stroll. Every extra 1,000 steps a patient takes daily after surgery lowers their odds of complications, researchers reported May 6 in the Journal of the American College of Surgeons. (Thompson, 5/7)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 21
  • Monday, July 20
  • Friday, July 17
  • Thursday, July 16
  • Wednesday, July 15
  • Tuesday, July 14
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ºÚÁϳԹÏÍø
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF